On the other hand, we observed downregulation of B3GNT5 in five tumors which include breast invasive carcinoma (BRCA), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), testicular germ cell tumor (TGCT), and thyroid carcinoma (THCA) (Fig 1A). This evidence concerns the gene B3GNT5 and prostate adenocarcinoma.